{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:37:37Z","timestamp":1761917857050,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment\u00a0Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12325-018-0717-x","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T15:31:09Z","timestamp":1528212669000},"page":"864-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial"],"prefix":"10.1007","volume":"35","author":[{"given":"Linong","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengnan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongwen","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuzai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuyan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"717_CR1","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1001\/jama.2017.7596","volume":"317","author":"L Wang","year":"2017","unstructured":"Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317:2515\u201323.","journal-title":"JAMA"},{"key":"717_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2013.168118","volume":"310","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948\u201359.","journal-title":"JAMA"},{"key":"717_CR3","unstructured":"International Diabetes Federation. Diabetes Atlas, 7th ed. Brussels: International Diabetes Federation, 2015. http:\/\/www.diabetesatlas.org. Accessed 21 Sep 2017."},{"key":"717_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2011.01.009","volume":"149","author":"TO Cheng","year":"2011","unstructured":"Cheng TO. Diabetes epidemic in China and its economic impact. Int J Cardiol. 2011;149:1\u20133.","journal-title":"Int J Cardiol"},{"key":"717_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc17-S001","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40:S1\u2013135.","journal-title":"Diabetes Care"},{"key":"717_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/dmrr.2827","volume":"32","author":"J Weng","year":"2016","unstructured":"Weng J, Ji L, Jia W, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32:442\u201358.","journal-title":"Diabetes Metab Res Rev"},{"key":"717_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/dia.2007.0265","volume":"10","author":"SA Schreiber","year":"2008","unstructured":"Schreiber SA, Ferlinz KandHaak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-months observational study of everyday clinical practice. Diabetes Technol Ther. 2008;10:121\u20137.","journal-title":"Diabetes Technol Ther"},{"key":"717_CR8","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/dom.12886","volume":"19","author":"L Ji","year":"2017","unstructured":"Ji L, Zhang P, Zhu D, et al. observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. Diabetes Obes Metab. 2017;19:822\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"717_CR9","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080\u20136.","journal-title":"Diabetes Care"},{"key":"717_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/1471-2458-13-602","volume":"13","author":"LN Ji","year":"2013","unstructured":"Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013;13:602.","journal-title":"BMC Public Health"},{"key":"717_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1753-0407.2011.00137.x","volume":"3","author":"ST Tsai","year":"2011","unstructured":"Tsai ST, Pathan F, Ji L, et al. First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3:208\u201316.","journal-title":"J Diabetes"},{"key":"717_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/dia.2011.0220","volume":"14","author":"M Odawara","year":"2012","unstructured":"Odawara M, Ohtani TandKadowaki T. Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis. Diabetes Technol Ther. 2012;14:635\u201343.","journal-title":"Diabetes Technol Ther"},{"key":"717_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4158\/EP161682.CS","volume":"23","author":"AJ Garber","year":"2017","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm\u20142017 executive summary. Endocr Pract. 2017;23:207\u201338.","journal-title":"Endocr Pract"},{"key":"717_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4239\/wjd.v5.i1.69","volume":"5","author":"DR Franco","year":"2014","unstructured":"Franco DR, Baptista J, Abreu FR, et al. Starting glargine in insulin-naive type 2 diabetic patients based on body mass index is safe. World J Diabetes. 2014;5:69\u201375.","journal-title":"World J Diabetes"},{"key":"717_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/03007995.2012.671764","volume":"28","author":"W Yang","year":"2012","unstructured":"Yang W, Lv X, Li Q, et al. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin. 2012;28:533\u201341.","journal-title":"Curr Med Res Opin"},{"key":"717_CR16","doi-asserted-by":"publisher","first-page":"e2863","DOI":"10.1002\/dmrr.2863","volume":"33","author":"B Zhang","year":"2017","unstructured":"Zhang B, Zhao J, Yang W, et al. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. Diabetes Metab Res Rev. 2017;33:e2863.","journal-title":"Diabetes Metab Res Rev"},{"key":"717_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4158\/EP14079.OR","volume":"21","author":"SK Garg","year":"2015","unstructured":"Garg SK, Admane K, Freemantle N, et al. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015;21:143\u201357.","journal-title":"Endocr Pract"},{"key":"717_CR18","unstructured":"Chow SC, Shao J, Wang H. Sample size calculations in clinical research, 2nd ed. Chapman Hall\/CRC Biostatistics Series; 2008."},{"key":"717_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.diabres.2014.08.003","volume":"106","author":"DR Owens","year":"2014","unstructured":"Owens DR, Traylor L, Dain MP, et al. Efficacy and safety of basal insulin glargine 12 and 24\u00a0weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Diabetes Res Clin Pract. 2014;106:264\u201374.","journal-title":"Diabetes Res Clin Pract"},{"key":"717_CR20","doi-asserted-by":"publisher","first-page":"e41358","DOI":"10.1371\/journal.pone.0041358","volume":"7","author":"T Kadowaki","year":"2012","unstructured":"Kadowaki T, Ohtani T, Naito Y, et al. Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis. PLoS One. 2012;7:e41358.","journal-title":"PLoS One"},{"key":"717_CR21","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.3760\/cma.j.issn.0366-6999.20140826","volume":"127","author":"L Ji","year":"2014","unstructured":"Ji L, Newman J, Lu J, et al. Understanding the standard of care in the treatment of type 2 diabetes in China: results from a national survey. Chin Med J (Engl). 2014;127:3524\u20139.","journal-title":"Chin Med J (Engl)"},{"key":"717_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40271-014-0068-x","volume":"7","author":"M Brod","year":"2014","unstructured":"Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. Patient. 2014;7:437\u201350.","journal-title":"Patient"},{"key":"717_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/JMDH.S64084","volume":"7","author":"MK Sorli CandHeile","year":"2014","unstructured":"Sorli CandHeile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc. 2014;7:267\u201382.","journal-title":"J Multidiscip Healthc"},{"key":"717_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/CLEP.S129268","volume":"9","author":"C Balijepalli","year":"2017","unstructured":"Balijepalli C, Druyts E, Siliman G, et al. Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. Clin Epidemiol. 2017;9:291\u20136.","journal-title":"Clin Epidemiol"},{"key":"717_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","volume":"23","author":"H Yki-Jarvinen","year":"2000","unstructured":"Yki-Jarvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group. Diabetes Care. 2000;23:1130\u20136.","journal-title":"Diabetes Care"},{"key":"717_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","volume":"295","author":"G Piaggio","year":"2006","unstructured":"Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152\u201360.","journal-title":"JAMA"},{"key":"717_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0717-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:26:48Z","timestamp":1724412408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0717-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"15 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}